Lincoln Pharmaceuticals Ltd
₹ 646
-0.68%
16 Jun
11:06 a.m.
About
Incorporated in 1979, Lincoln Pharmaceuticals Ltd is in the business of manufacturing and trading of pharmaceutical products [1]
Key Points
- Market Cap ₹ 1,295 Cr.
- Current Price ₹ 646
- High / Low ₹ 770 / 440
- Stock P/E 14.8
- Book Value ₹ 378
- Dividend Yield 0.28 %
- ROCE 16.3 %
- ROE 12.3 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of 9.67% over past five years.
- Company has a low return on equity of 13.8% over last 3 years.
- Earnings include an other income of Rs.33.4 Cr.
- Dividend payout has been low at 4.11% of profits over last 3 years
- Working capital days have increased from 159 days to 239 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 223 | 311 | 304 | 325 | 353 | 376 | 423 | 472 | 510 | 581 | 623 | 671 | |
| 200 | 278 | 261 | 279 | 292 | 317 | 336 | 376 | 421 | 480 | 522 | 573 | |
| Operating Profit | 23 | 33 | 43 | 46 | 61 | 60 | 87 | 96 | 90 | 100 | 102 | 98 |
| OPM % | 10% | 11% | 14% | 14% | 17% | 16% | 21% | 20% | 18% | 17% | 16% | 15% |
| 5 | 6 | 2 | 6 | 6 | 12 | 6 | 10 | 22 | 34 | 22 | 33 | |
| Interest | 6 | 6 | 5 | 4 | 4 | 2 | 2 | 1 | 2 | 1 | 2 | 1 |
| Depreciation | 3 | 3 | 4 | 4 | 5 | 5 | 8 | 8 | 9 | 11 | 13 | 14 |
| Profit before tax | 19 | 30 | 36 | 43 | 58 | 64 | 84 | 96 | 100 | 122 | 109 | 116 |
| Tax % | 23% | 28% | 23% | 24% | 20% | 23% | 26% | 28% | 27% | 24% | 25% | 24% |
| 15 | 22 | 27 | 33 | 47 | 50 | 62 | 69 | 73 | 93 | 82 | 88 | |
| EPS in Rs | 9.06 | 13.33 | 13.70 | 16.38 | 23.32 | 24.78 | 31.12 | 34.62 | 36.40 | 46.58 | 41.11 | 43.88 |
| Dividend Payout % | 11% | 8% | 9% | 9% | 6% | 6% | 5% | 4% | 4% | 4% | 4% | 4% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 10% |
| 3 Years: | 10% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 7% |
| 3 Years: | 7% |
| TTM: | 8% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 15% |
| 3 Years: | 19% |
| 1 Year: | 13% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 15% |
| 3 Years: | 14% |
| Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
| Reserves | 95 | 122 | 170 | 200 | 243 | 284 | 346 | 413 | 482 | 573 | 652 | 738 |
| 48 | 61 | 53 | 56 | 34 | 5 | 1 | 2 | 2 | 1 | 0 | 4 | |
| 32 | 43 | 39 | 50 | 51 | 58 | 85 | 99 | 83 | 106 | 125 | 128 | |
| Total Liabilities | 192 | 242 | 282 | 326 | 347 | 367 | 452 | 534 | 587 | 700 | 797 | 890 |
| 33 | 63 | 68 | 83 | 88 | 91 | 111 | 132 | 151 | 179 | 182 | 191 | |
| CWIP | 3 | 3 | 7 | 0 | 2 | 0 | 2 | 16 | 7 | 3 | 4 | 5 |
| Investments | 13 | 20 | 36 | 39 | 46 | 60 | 81 | 97 | 91 | 139 | 174 | 209 |
| 143 | 156 | 171 | 204 | 211 | 216 | 259 | 289 | 339 | 378 | 437 | 485 | |
| Total Assets | 192 | 242 | 282 | 326 | 347 | 367 | 452 | 534 | 587 | 700 | 797 | 890 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 | 29 | 18 | 21 | 51 | 71 | 69 | 76 | 39 | 63 | 93 | 106 | |
| -5 | -40 | -26 | -14 | -22 | -29 | -64 | -78 | -37 | -57 | -79 | -98 | |
| -5 | 11 | 8 | -4 | -30 | -38 | -6 | -3 | -4 | -5 | -6 | 0 | |
| Net Cash Flow | -1 | -0 | -0 | 4 | -1 | 4 | -1 | -4 | -2 | 1 | 8 | 8 |
| Free Cash Flow | 5 | -4 | 1 | 12 | 40 | 65 | 61 | 31 | 26 | 24 | 74 | 82 |
| CFO/OP | 53% | 107% | 62% | 65% | 112% | 142% | 102% | 104% | 77% | 89% | 117% | 135% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 135 | 88 | 95 | 108 | 117 | 88 | 97 | 89 | 97 | 101 | 97 | 87 |
| Inventory Days | 49 | 44 | 67 | 78 | 61 | 73 | 86 | 121 | 106 | 101 | 99 | 94 |
| Days Payable | 34 | 37 | 53 | 75 | 74 | 82 | 105 | 119 | 77 | 95 | 106 | 99 |
| Cash Conversion Cycle | 150 | 96 | 110 | 111 | 104 | 80 | 78 | 91 | 126 | 108 | 89 | 82 |
| Working Capital Days | 83 | 50 | 74 | 90 | 96 | 111 | 120 | 114 | 121 | 121 | 116 | 239 |
| ROCE % | 16% | 20% | 19% | 18% | 22% | 22% | 25% | 24% | 22% | 22% | 17% | 16% |
Insights
In beta| Mar 2013 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenditure as % of Sales % |
|
|||||||||
| Export Sales Contribution % |
||||||||||
| Annual Production Capacity - Capsules (Unit 1) Lacs |
||||||||||
| Annual Production Capacity - Cephalosporin OSD Tablets Lacs |
||||||||||
| Annual Production Capacity - Liquid Ampoules (Unit 2) Ampoules |
||||||||||
| Annual Production Capacity - Liquid Vials (Unit 2) Vials |
||||||||||
| Domestic Field Force (MRs) Count |
||||||||||
| Global Presence (Countries) Count |
||||||||||
| Products in Pipeline/Registration Count |
||||||||||
| Total Registered Products Count |
||||||||||
| R&D Expenditure (Percentage of Turnover) % |
||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
29 May - We enclosed herewith the copies of published newspaper advertisement with respect to Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and …
-
Corporate Action-Board approves Dividend
28 May - Board approved audited FY26 results and recommended 18% dividend of Rs 1.80 per share.
- Audited Financial Results For The Quarter And Year Ended 31St March, 2026 28 May
-
Board Meeting Outcome for Board Meeting Outcome For Audited Financial Results For The Quarter And Year Ended 31St March, 2026.
28 May - Lincoln Pharmaceuticals approved FY26 audited results and recommended 18% dividend on May 28, 2026.
-
Corporate Action-Board to consider Dividend
18 May - Board meets May 28, 2026 to approve audited FY26 results and consider dividend.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Feb 2026Transcript PPT REC
-
Nov 2025TranscriptAI SummaryPPT
-
Aug 2025TranscriptAI SummaryPPT
-
May 2025TranscriptAI SummaryPPT
-
Feb 2025TranscriptAI SummaryPPT
-
Nov 2024TranscriptAI SummaryPPT
-
Jun 2024TranscriptAI SummaryPPT
-
May 2024Transcript PPT REC
-
Feb 2024TranscriptAI SummaryPPT
-
Oct 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Nov 2022TranscriptAI SummaryPPT
-
Jul 2022TranscriptAI SummaryPPT
-
Apr 2021TranscriptAI SummaryPPT
-
Jan 2021TranscriptAI SummaryPPT
-
Oct 2020TranscriptAI SummaryPPT
-
Jul 2020TranscriptAI SummaryPPT
-
Apr 2020TranscriptAI SummaryPPT
-
Jan 2020TranscriptAI SummaryPPT
-
Oct 2019TranscriptAI SummaryPPT
-
Jul 2019TranscriptAI SummaryPPT
-
Apr 2019TranscriptAI SummaryPPT
-
Jan 2019TranscriptAI SummaryPPT
-
Oct 2018TranscriptAI SummaryPPT
-
Jul 2018TranscriptAI SummaryPPT
-
Apr 2018TranscriptAI SummaryPPT
-
Jan 2018TranscriptAI SummaryPPT
-
Oct 2017TranscriptAI SummaryPPT
-
Jul 2017TranscriptAI SummaryPPT
-
Aug 2016TranscriptAI SummaryPPT
Product Profile:[1]
LPL has developed 600+ formulations in 15 therapeutic areas and has 1700
registered products with another 700 in the pipeline. It also has 7 patented products and has filed applications for 25+ patents